{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T15:52:13Z","timestamp":1789228333425,"version":"build-2803163510"},"reference-count":32,"publisher":"MDPI AG","issue":"23","license":[{"start":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T00:00:00Z","timestamp":1764374400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004587","name":"ISCIII FEDER","doi-asserted-by":"publisher","award":["PI21\/01292"],"award-info":[{"award-number":["PI21\/01292"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"ISCIII RETICS REDinREN","doi-asserted-by":"publisher","award":["PI24\/01510"],"award-info":[{"award-number":["PI24\/01510"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"name":"ERA PerMed JTC2022","award":["AC22\/00029"],"award-info":[{"award-number":["AC22\/00029"]}]},{"name":"R\u00edo Hortega","award":["CM23\/00213"],"award-info":[{"award-number":["CM23\/00213"]}]},{"name":"R\u00edo Hortega","award":["INT24\/00067"],"award-info":[{"award-number":["INT24\/00067"]}]},{"name":"RICORS","award":["RD21\/0005\/0016"],"award-info":[{"award-number":["RD21\/0005\/0016"]}]},{"name":"RICORS","award":["RD24\/0004\/0031"],"award-info":[{"award-number":["RD24\/0004\/0031"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Patients with diabetes and chronic kidney disease (CKD-DM) often have residual albuminuria despite pharmacological treatment. Finerenone targets mineralocorticoid overactivation, but real-world evidence remains limited. This study evaluated the impact of finerenone in a cohort of patients with CKD-DM. This was a real-life study including patients with CKD-DM and an estimated glomerular filtration rate (eGFR) \u2265 20 mL\/min\/1.73 m2, treated with finerenone, aged \u2265 18 years, and followed at the Nephrology Department of Vall d\u2019Hebron Hospital. Clinical and laboratory data were collected at baseline and at 1, 3, and 6 months of treatment. Changes in albuminuria and eGFR were analyzed in patients who completed 6 months of follow-up. A total of 60 patients were included in the analysis; 39 (65%) were male, with a median age of 79 \u00b1 10.12 years. Finerenone was initiated at 10 mg daily in 57 patients (95%), with 38.3% escalating to 20 mg after 1 month. After 6 months, the urinary albumin-to-creatinine ratio (UACR) decreased by 37.1% (p = 0.012, n = 34). Patients with an initial eGFR drop &gt; 20% showed a greater UACR decrease of around 43% at 3 (p = 0.012) and 6 months (p = 0.013). A significant 9.5% decline in eGFR was observed at 1 month, followed by stabilization at 3 and 6 months. Finerenone was discontinued in 10% of the patients due to adverse events. Hyperkalemia occurred in 18.3% of the patients, but no hospitalizations for adverse events or heart failure were reported. In summary, finerenone induced a significant 37.1% reduction in albuminuria after 6 months of treatment. This reduction was more pronounced in patients who experienced an initial eGFR dip \u2265 20%. Finerenone was generally well tolerated and appears to be a promising therapeutic strategy for reducing albuminuria in this population.<\/jats:p>","DOI":"10.3390\/ijms262311584","type":"journal-article","created":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T08:13:49Z","timestamp":1764576829000},"page":"11584","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Real-World Impact of Finerenone on Albuminuria in Patients with Diabetes and CKD"],"prefix":"10.3390","volume":"26","author":[{"given":"Marina","family":"L\u00f3pez-Mart\u00ednez","sequence":"first","affiliation":[{"name":"Department of Nephrology, Vall d\u2019Hebron University Hospital, Pg. de la Vall d\u2019Hebron, 119, 08035 Barcelona, Spain"},{"name":"Department of Medicine, Universitat Aut\u00f2noma de Barcelona, 08193 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Le\u00f3n-Rom\u00e1n","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Vall d\u2019Hebron University Hospital, Pg. de la Vall d\u2019Hebron, 119, 08035 Barcelona, Spain"},{"name":"Department of Medicine, Universitat Aut\u00f2noma de Barcelona, 08193 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ehimy","family":"Su\u00e1rez","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Vall d\u2019Hebron University Hospital, Pg. de la Vall d\u2019Hebron, 119, 08035 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Nu\u00f1ez-Delgado","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Vall d\u2019Hebron University Hospital, Pg. de la Vall d\u2019Hebron, 119, 08035 Barcelona, Spain"},{"name":"Department of Medicine, Universitat Aut\u00f2noma de Barcelona, 08193 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Antonieta Azancot","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Vall d\u2019Hebron University Hospital, Pg. de la Vall d\u2019Hebron, 119, 08035 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-0423-703X","authenticated-orcid":false,"given":"Jorge Iv\u00e1n","family":"Zamora-Carrillo","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Vall d\u2019Hebron University Hospital, Pg. de la Vall d\u2019Hebron, 119, 08035 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Patricio-Li\u00e9bana","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Vall d\u2019Hebron University Hospital, Pg. de la Vall d\u2019Hebron, 119, 08035 Barcelona, Spain"},{"name":"Department of Medicine, Universitat Aut\u00f2noma de Barcelona, 08193 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"S\u00e1nchez Olaya","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Vall d\u2019Hebron University Hospital, Pg. de la Vall d\u2019Hebron, 119, 08035 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Agraz","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Vall d\u2019Hebron University Hospital, Pg. de la Vall d\u2019Hebron, 119, 08035 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3611-4830","authenticated-orcid":false,"given":"Sheila","family":"Bermejo","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Vall d\u2019Hebron University Hospital, Pg. de la Vall d\u2019Hebron, 119, 08035 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laia","family":"Sans","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Vall d\u2019Hebron University Hospital, Pg. de la Vall d\u2019Hebron, 119, 08035 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nestor","family":"Toapanta","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Vall d\u2019Hebron University Hospital, Pg. de la Vall d\u2019Hebron, 119, 08035 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9832-326X","authenticated-orcid":false,"given":"Natalia","family":"Ramos","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Vall d\u2019Hebron University Hospital, Pg. de la Vall d\u2019Hebron, 119, 08035 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3621-0766","authenticated-orcid":false,"given":"Mar\u00eda Jos\u00e9","family":"Soler","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Vall d\u2019Hebron University Hospital, Pg. de la Vall d\u2019Hebron, 119, 08035 Barcelona, Spain"},{"name":"Department of Medicine, Universitat Aut\u00f2noma de Barcelona, 08193 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,11,29]]},"reference":[{"key":"ref_1","unstructured":"(2025, November 06). World Health Organization. Available online: https:\/\/www.Who.Int\/News-Room\/Fact-Sheets\/Detail\/Diabetes."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.nefroe.2023.09.002","article-title":"Finerenone: Towards a Holistic Therapeutic Approach to Patients with Diabetic Kidney Disease","volume":"43","author":"Facila","year":"2023","journal-title":"Nefrol. (Engl. Ed.)"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/s41581-021-00393-8","article-title":"Pathophysiology of Diabetic Kidney Disease: Impact of SGLT2 Inhibitors","volume":"17","author":"DeFronzo","year":"2021","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1038\/s41366-019-0476-z","article-title":"The Estimation of GFR and the Adjustment for BSA in Overweight and Obesity: A Dreadful Combination of Two Errors","volume":"44","author":"Morales","year":"2020","journal-title":"Int. J. Obes."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Luis-Lima, S., Higueras Linares, T., Henr\u00edquez-G\u00f3mez, L., Alonso-Pescoso, R., Jimenez, A., L\u00f3pez-Hijazo, A.M., Negr\u00edn-Mena, N., Mart\u00edn, C., S\u00e1nchez-Gallego, M., and Galindo-Hern\u00e1ndez, S.J. (2019). The Error of Estimated GFR in Type 2 Diabetes Mellitus. J. Clin. Med., 8.","DOI":"10.3390\/jcm8101543"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1093\/ckj\/sfac019","article-title":"The 2021 European Society of Cardiology Cardiovascular Disease Prevention Guidelines: Adding Albuminuria to the SCORE Scale Increases the Prevalence of Very High\/High Cardiovascular Risk Among Patients with Chronic Kidney Disease","volume":"15","author":"Cebrian","year":"2022","journal-title":"Clin. Kidney J."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/S0140-6736(21)00519-5","article-title":"Chronic Kidney Disease","volume":"398","author":"Jafar","year":"2021","journal-title":"Lancet"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"sfae039","DOI":"10.1093\/ckj\/sfae039","article-title":"Are We Ready for an Adipocentric Approach in People Living with Type 2 Diabetes and Chronic Kidney Disease?","volume":"17","author":"Soler","year":"2024","journal-title":"Clin. Kidney J."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in Patients with Chronic Kidney Disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.nefro.2020.10.001","article-title":"Bloqueantes del Receptor Mineralcorticoide en la Enfermedad Renal Cr\u00f3nica","volume":"41","author":"Erraez","year":"2021","journal-title":"Nefrolog\u00eda"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1001\/jama.2015.10081","article-title":"Effect of Finerenone on Albuminuria in Patients with Diabetic Nephropathy","volume":"314","author":"Bakris","year":"2015","journal-title":"JAMA"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and Kidney Outcomes with Finerenone in Patients with Type 2 Diabetes and Chronic Kidney Disease: The FIDELITY Pooled Analysis","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur. Heart J."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.7326\/M23-1023","article-title":"Impact of Finerenone-Induced Albuminuria Reduction on Chronic Kidney Disease Outcomes in Type 2 Diabetes: A Mediation Analysis","volume":"176","author":"Agarwal","year":"2023","journal-title":"Ann. Intern. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1161\/CIRCULATIONAHA.123.067584","article-title":"Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment with SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared with Conventional Care in Patients with Type 2 Diabetes and Albuminuria","volume":"149","author":"Neuen","year":"2024","journal-title":"Circulation"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1080\/07853890.2023.2171110","article-title":"Cardiorenal Benefits of Finerenone: Protecting Kidney and Heart","volume":"55","author":"Ortiz","year":"2023","journal-title":"Ann. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1007\/s40262-022-01124-3","article-title":"Dose\u2013Exposure\u2013Response Analysis of the Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone on UACR and EGFR: An Analysis from FIDELIO-DKD","volume":"61","author":"Goulooze","year":"2022","journal-title":"Clin. Pharmacokinet."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1038\/s41440-025-02175-2","article-title":"Real-World Use of Finerenone in Patients with Chronic Kidney Disease and Type 2 Diabetes Based on Large-Scale Clinical Studies: FIDELIO-DKD and FIGARO-DKD","volume":"48","author":"Sato","year":"2025","journal-title":"Hypertens. Res."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Lv, R., Xu, L., Che, L., Liu, S., Wang, Y., and Dong, B. (2023). Cardiovascular-Renal Protective Effect and Molecular Mechanism of Finerenone in Type 2 Diabetic Mellitus. Front. Endocrinol., 14.","DOI":"10.3389\/fendo.2023.1125693"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Yao, L., Liang, X., Liu, Y., Li, B., Hong, M., Wang, X., Chen, B., Liu, Z., and Wang, P. (2023). Non-Steroidal Mineralocorticoid Receptor Antagonist Finerenone Ameliorates Mitochondrial Dysfunction via PI3K\/Akt\/ENOS Signaling Pathway in Diabetic Tubulopathy. Redox Biol., 68.","DOI":"10.1016\/j.redox.2023.102946"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Jerome, J.R., Deliyanti, D., Suphapimol, V., Kolkhof, P., and Wilkinson-Berka, J.L. (2023). Finerenone, a Non-Steroidal Mineralocorticoid Receptor Antagonist, Reduces Vascular Injury and Increases Regulatory T-Cells: Studies in Rodents with Diabetic and Neovascular Retinopathy. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24032334"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Gonz\u00e1lez-Bl\u00e1zquez, R., Somoza, B., Gil-Ortega, M., Mart\u00edn Ramos, M., Ramiro-Cortijo, D., Vega-Mart\u00edn, E., Schulz, A., Ruilope, L.M., Kolkhof, P., and Kreutz, R. (2018). Finerenone Attenuates Endothelial Dysfunction and Albuminuria in a Chronic Kidney Disease Model by a Reduction in Oxidative Stress. Front. Pharmacol., 9.","DOI":"10.3389\/fphar.2018.01131"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1681\/ASN.0000000000000426","article-title":"Association Between Acute Declines in EGFR During Renin-Angiotensin System Inhibition and Risk of Adverse Outcomes","volume":"35","author":"Ku","year":"2024","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/ki.2011.79","article-title":"An Acute Fall in Estimated Glomerular Filtration Rate During Treatment with Losartan Predicts a Slower Decrease in Long-Term Renal Function","volume":"80","author":"Holtkamp","year":"2011","journal-title":"Kidney Int."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.kint.2024.05.024","article-title":"A Meta-Analysis of Randomized Controlled Clinical Trials for Implications of Acute Treatment Effects on Glomerular Filtration Rate for Long-Term Kidney Protection","volume":"106","author":"Heerspink","year":"2024","journal-title":"Kidney Int."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.2215\/CJN.01130121","article-title":"Ertugliflozin and Slope of Chronic EGFR","volume":"16","author":"Cherney","year":"2021","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.kint.2020.10.031","article-title":"Characterization and Implications of the Initial Estimated Glomerular Filtration Rate \u2018Dip\u2019 upon Sodium-Glucose Cotransporter-2 Inhibition with Empagliflozin in the EMPA-REG OUTCOME Trial","volume":"99","author":"Kraus","year":"2021","journal-title":"Kidney Int."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.kint.2025.03.018","article-title":"Efficacy and safety of finerenone in patients with an acute change in estimated glomerular filtration rate in the prespecified FIDELITY pool analysis","volume":"108","author":"Navaneethan","year":"2025","journal-title":"Kidney Int."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jacc.2024.11.020","article-title":"Initial Decline in Glomerular Filtration Rate with Finerenone in HFmrEF\/HFpEF","volume":"85","author":"Matsumoto","year":"2025","journal-title":"J. Am. Coll. Cardiol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/23\/11584\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T08:28:04Z","timestamp":1764577684000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/23\/11584"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,29]]},"references-count":32,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["ijms262311584"],"URL":"https:\/\/doi.org\/10.3390\/ijms262311584","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,29]]}}}